Browse through all publications from the Institute of Global Health Innovation, which our Patient Safety Research Collaboration is part of. This feed includes reports and research papers from our Centre. 

Citation

BibTex format

@article{Aggarwal:2026:10.1002/npr2.70146,
author = {Aggarwal, A and Erridge, S and Varadpande, M and Clarke, E and McLachlan, K and Coomber, R and Asghar, M and Bhoskar, U and Crews, M and De, Angelis A and Imran, M and Kamal, F and Korb, L and Mwimba, G and Sachdeva-Mohan, S and Shaya, G and Rucker, JJ and Sodergren, MH},
doi = {10.1002/npr2.70146},
journal = {Neuropsychopharmacol Rep},
title = {UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder.},
url = {http://dx.doi.org/10.1002/npr2.70146},
volume = {46},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: Autism spectrum disorder (ASD) is a neurodevelopmental disorder associated with distressed behaviors and psychological challenges. This study aims to evaluate the change in health-related quality of life (HRQoL), anxiety, and sleep quality in autistic individuals prescribed cannabis-based medicinal products (CBMPs). METHOD: This observational case series analyzed data from the UK Medical Cannabis Registry on autistic adults treated with CBMPs. Demographic and clinical data were collected at baseline, with patient-reported outcome measures assessed up to 18 months. Primary outcomes included changes in anxiety (GAD-7), sleep quality (SQS), and HRQoL (EQ-5D-5L). Secondary outcomes included the incidence of adverse events. Statistical significance was indicated by p < 0.050. RESULTS: One-hundred and thirty individuals met the inclusion criteria. GAD-7 (p < 0.001) and SQS (p < 0.001) scores improved from baseline to 18 months. EQ-5D-5L index values showed improvement from baseline (0.43 ± 0.30) to 18 months (0.51 ± 0.32, p < 0.001), and PGIC scores increased from 1 month (5.43 ± 1.49) to 18 months (5.65 ± 1.32, p = 0.013). Twenty-five participants (19.23%) reported a total of 232 (178.46%) adverse events, with most being mild (n = 88; 67.69%) or moderate (n = 99; 76.15%). CONCLUSION: Treatment with CBMPs was associated with improvements in HRQoL, anxiety, and sleep outcomes in autistic patients over an 18-month period. Given the absence of a control group, these findings represent associations rather than proven treatment effects. Further high-quality randomized controlled trials are needed to confirm the long-term efficacy and safety of CBMPs in ASD.
AU  - Aggarwal,A
AU  - Erridge,S
AU  - Varadpande,M
AU  - Clarke,E
AU  - McLachlan,K
AU  - Coomber,R
AU  - Asghar,M
AU  - Bhoskar,U
AU  - Crews,M
AU  - De,Angelis A
AU  - Imran,M
AU  - Kamal,F
AU  - Korb,L
AU  - Mwimba,G
AU  - Sachdeva-Mohan,S
AU  - Shaya,G
AU  - Rucker,JJ
AU  - Sodergren,MH
DO  - 10.1002/npr2.70146
PY  - 2026///
TI  - UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Autism Spectrum Disorder.
T2  - Neuropsychopharmacol Rep
UR  - http://dx.doi.org/10.1002/npr2.70146
UR  - https://www.ncbi.nlm.nih.gov/pubmed/42387975
VL  - 46
ER  -
Download